Year: 2025
Type: article
Abstract: Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for approximately 20% of all breast cancer cases. The advent of therapies targeting HER2 has significantly improved the prognosis for HER2-positive breast cancer. Neoadjuvant/adjuvant chemotherapy with HER2-targeted agents is recommended for early and locally advanced breast cancer. The appropriate use of novel HER2-targeted therapies is recommended for metastatic breast. We aimed to examine the diagnosis and personalized treatment for HER2-positive breast cancer.
Source: Korean Journal of Medicine
Author: Suee Lee
Institutions: Dong-A University Hospital, Dong-A University
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funder: Dong-A University
OpenAlex ID: W4409203097